References
- Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T et al., Mode of action, in vitro activity and in vivo efficacy of AFN-1252, a selective anti-staphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56:5865–74.
- Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ et al., In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007;51:1580–1.
- Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother. 2009;53:3544–8.
- Banevicius M, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother. 2013;25(1):18–25.
- Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW et al., In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J Chemother. 2013;25(1):18–25.
- Kaplan N, Garner C, Hafkin B. AFN-1252 In vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur J Pharm Sci. 2013;50(3-4):440–6.
- Kaplan N, Flanner H, Hafkin B. Correlation of AFN-1252 Phase 0 microdosing and phase 1 pharmacokinetics, Abstr F1-2006. 49th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC: American Society for Microbiology 2009..
- Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot. 2010;63(8):423–30.
- Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB et al., Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011. Available from: http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=998 2011.
- Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol. 2011;14(5):564–9.
- Hafkin B, Kaplan N, Hunt T. Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects. Future Microbiol. 2015;10:1805–13
- Tsuji BT, Harigaya Y, Lesse AJ, Forrest A, Ngo D. Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013;25(1):32–5.